Catalog No.
VHC09603
Species reactivity
Human
Host species
Mouse
Isotype
IgG
Clonality
Monoclonal
Target
Bispecific, Receptor tyrosine-protein kinase erbB-2, 2.7.10.1, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, HER2, MLN19, NEU, NGL, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T3E
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04626 & P07766
Applications
FuncS
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0231
[Comparison of the efficacy, safety, and cost-effectiveness of trastuzumab biosimilar HLX02 and the originator combined with pertuzumab and chemotherapy in the neoadjuvant treatment of patients with HER-2-positive breast cancer]., PMID:40534267
Neburon induced cardiotoxicity in embryonic and adult male zebrafish via over-activation of the Ahr-Notch1 signaling pathway., PMID:40532808
Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer., PMID:40532664
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial., PMID:40526879
Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights., PMID:40526089
Real-world treatment patterns and outcomes of patients with hormone receptor-positive/HER2-low metastatic breast cancer treated with chemotherapy., PMID:40525913
Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients., PMID:40524202
Clinical Efficacy and Safety of Apatinib Combined with Irinotecan in HER2-negative Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First-Line Treatment Failure: A Single-Arm, Single-Center Retrospective Study., PMID:40524072
Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer., PMID:40519936
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study., PMID:40514709
Dynamics of mitochondrial DNA copy number regulation in relation to gastric cancer survival., PMID:40514632
A tunable gene therapy for heart regeneration., PMID:40514437
Di (2-ethylhexyl) Phthalate decrease pregnancy rate via disrupting the microbe-gut-hypothalamic-pituitary-ovarian axis in mice., PMID:40514374
Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type., PMID:40512776
Genomic Signatures of Gastric Adenocarcinoma By Tumor Location-Modified Laurén Classification: Highlighting the Molecular Heterogeneity of Mixed-Type Tumors., PMID:40512601
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial., PMID:40512191
Knockdown of Claudin-8 (CLDN8) Indicates a Link Between Breast Cancer Cell Sensitivity to Chemotherapeutics and Reveals a Potential Use of CLDN8 as a Molecular Diagnostic and Target for Therapy., PMID:40508219
Sex Hormones and Iron-Related Biomarkers Associate with EMT Features and Tumor Stage in Colorectal Cancer: A Serum- and Tissue-Based Analysis., PMID:40507970
Mutational Patterns in Colorectal Cancer: Do PDX Models Retain the Heterogeneity of the Original Tumor?, PMID:40507920
Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement., PMID:40507325
Clinical Application of Next-Generation Sequencing for Molecular Classification in the Management of Endometrial Cancer: An Observational Cohort Study., PMID:40507285
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature., PMID:40506517
Hereditary breast cancer beyond BRCA: clinicopathological characteristics and long-term outcomes., PMID:40504267
RNF213-Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells., PMID:40503863
Analytical validation of Aspyre Clinical Test for Lung (Blood): A multiplexed PCR and pyrophosphorolysis-based assay for detecting actionable NSCLC variants in plasma cfDNA and cfRNA., PMID:40503460
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience., PMID:40503459
Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma., PMID:40502048
Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study., PMID:40500959
ERBB2-Low Expression by Race and Ethnicity Among Patients With Triple-Negative Breast Cancer., PMID:40498483
Noninvasive markers for warning premature ovarian insufficiency: a Mendelian randomisation study., PMID:40495196
Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation., PMID:40494858
Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer., PMID:40489875
Mechanisms Underlying the Therapeutic Effects of Brucea javanica in Cervical Cancer Treatment Based on Network Pharmacology and Molecular Docking., PMID:40487864
Improved Sampling Method to Enhance the Positive Rate of HER2 Detection in Gastric Cancer., PMID:40485523
Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype., PMID:40482645
Axillary staging with 18F-FDG PET/CT in early breast cancer: impact of tumor subtypes., PMID:40482189
A homogeneous mass-encoded strategy for mass spectrometric biosensing of multiplex proteins., PMID:40480694
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers., PMID:40480221
NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition., PMID:40473905
Are ERBB2 RNA-High, Amplification-Negative Tumors a Missed Opportunity for Targeted Therapy?, PMID:40472940
Is the Molecular Classification of ERBB2 in Stage III Colon Cancer Clinically Ready?, PMID:40472938
Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040
Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report., PMID:40470107
Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report., PMID:40469473
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors., PMID:40469307
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999
Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744
Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials., PMID:40468250
Novel receptor tyrosine kinase-targeted strategies to overcome resistance in oral squamous cell carcinoma., PMID:40468099
Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer., PMID:40467708
For research use only. Not for human or drug use.
